Key result
Transcatheter pulmonary artery denervation in patients with HF-rEF and Cpc-PH resulted in hemodynamic improvements in 50% (5 of 10) of patients at 6 months, while 3 patients died.
Why the study?
Pulmonary hypertension in patients with left ventricular systolic dysfunction has a negative impact on outcome, prompting investigation into transcatheter pulmonary artery denervation for combined postcapillary and precapillary pulmonary hypertension.
Does transcatheter pulmonary artery denervation improve hemodynamics and functional capacity in patients with HF-rEF and combined precapillary and postcapillary pulmonary hypertension?
Does transcatheter pulmonary artery denervation improve hemodynamics and functional capacity in patients with HF-rEF and combined precapillary and postcapillary pulmonary hypertension?
Transcatheter pulmonary artery denervation may improve hemodynamics in a subset of high-risk patients with HF-rEF and combined pre- and post-capillary pulmonary hypertension, potentially bridging them to advanced heart failure therapies.
OBJECTIVES: The present study was a prospective, single-center, single-arm study to investigate the efficacy of transcatheter pulmonary artery denervation (TPADN) in patients with combined postcapillary and precapillary PH (Cpc-PH) associated with left heart failure with reduced ejection fraction (HF-rEF). BACKGROUND: Pulmonary hypertension (PH) in patients with left ventricular systolic dysfunction has a negative impact on outcome. METHODS: The combination of pulmonary artery systolic pressure (PAPs) ≥60 mmHg, transpulmonary pressure gradient (TPG) ≥12 mmHg, nonreversible mean PAP, and pulmonary vascular resistance (PVR) ≥3.5 Wood Units was considered as too high risk for heart transplantation (HTx). The clinical efficacy endpoint was an improvement in 6-min walking test and the hemodynamic endpoints were changes in PAPs, PVR, and TPG between baseline and 6 months. Circumferential radiofrequency applications were delivered around distal main, left and right pulmonary arteries. At each ablation point temperature was 45°C and energy 10 W. RESULTS: TPADN was performed in 10 patients. At 6-month in 5 patients we observed reduction in PAP, PVR, TPG, and DPG and then 1 had successful HTx, 2 are on HTx waiting list, 2 received LVADs, 2 patients did not improve, and 3 patients died. CONCLUSIONS: TPADN may be beneficial in selected patients with HF-rEF and Cpc-PH.
No takes yet. Share an insight, caveat, or question.
Witkowski et al. (2021) studied Left heart failure with reduced ejection fraction and combined precapillary and postcapillary pulmonary hypertension (n=10). Transcatheter pulmonary artery denervation (TPADN) was evaluated on Improvement in 6-min walking test and changes in PAPs, PVR, and TPG between baseline and 6 months. Transcatheter pulmonary artery denervation in patients with HF-rEF and Cpc-PH resulted in hemodynamic improvements in 50% (5 of 10) of patients at 6 months, while 3 patients died.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: